CRISPRa genome-wide screen identifies novel gene targets for osteogenic cell engineering

Area of Science:

• Biotechnology
• Regenerative Medicine
• Stem Cell Biology

Background:

• Bone regeneration and fracture healing face challenges, with 5-10% of treatments resulting in nonunion.
• Autologous bone grafts, the standard treatment, have drawbacks including donor-site morbidity and high failure rates.
• Cell therapies and tissue engineering offer promising alternatives to traditional bone grafting methods.

Purpose of the Study:

• To investigate CRISPR-activation (CRISPRa) as a tool to induce osteogenesis in stem cells without exogenous growth factors.
• To identify novel gene targets that promote osteogenesis using a genome-wide CRISPRa screen.
• To validate the osteogenic potential of identified targets in adipose-derived stem cells (ASCs).

Main Methods:

• Conducted a genome-wide CRISPRa screen in ASCs to identify genes that drive osteogenesis.
• Utilized CRISPR-activation technology for targeted gene upregulation.
• Assessed osteogenic markers, including alkaline phosphatase activity and mineralization, in both monolayer and 3D cultures.

Main Results:

• Identified SPRED2 and ATXN7L3B as top targets from the CRISPRa screen that significantly enhance osteogenesis.
• Demonstrated increased alkaline phosphatase activity and mineralization in ASCs upon upregulation of SPRED2 and ATXN7L3B.
• Provided the first evidence of SPRED2 and ATXN7L3B as osteogenic targets in ASCs.

Conclusions:

• CRISPR-activation is an effective cell-engineering tool for driving osteogenesis without exogenous growth factors.
• SPRED2 and ATXN7L3B are novel targets that can be leveraged to enhance bone tissue regeneration.
• This approach holds potential for improving outcomes in bone healing treatments and reducing reliance on autologous bone grafts.